Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/162611
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWilliams, Hywel C.en_US
dc.contributor.authorSchmitt, Jochenen_US
dc.contributor.authorThomas, Kim S.en_US
dc.contributor.authorSpuls, Phyllis I.en_US
dc.contributor.authorSimpson, Eric L.en_US
dc.contributor.authorApfelbacher, Christianen_US
dc.contributor.authorChalmers, Joanne R.en_US
dc.contributor.authorFurue, Masutakaen_US
dc.contributor.authorKatoh, Noritoen_US
dc.contributor.authorGerbens, Louise A. A.en_US
dc.contributor.authorLeshem, Yael A.en_US
dc.contributor.authorHowells, Lauraen_US
dc.contributor.authorSingh, Jasvinder A.en_US
dc.contributor.authorBoers, Maartenen_US
dc.date.accessioned2022-11-01T03:07:57Z-
dc.date.available2022-11-01T03:07:57Z-
dc.date.issued2022-
dc.identifier.citationWilliams, H. C., Schmitt, J., Thomas, K. S., Spuls, P. I., Simpson, E. L., Apfelbacher, C., Chalmers, J. R., Furue, M., Katoh, N., Gerbens, L. A. A., Leshem, Y. A., Howells, L., Singh, J. A. & Boers, M. (2022). The HOME Core outcome set for clinical trials of atopic dermatitis. Journal of Allergy and Clinical Immunology, 149(6), 1899-1911. https://dx.doi.org/10.1016/j.jaci.2022.03.017en_US
dc.identifier.issn0091-6749en_US
dc.identifier.urihttps://hdl.handle.net/10356/162611-
dc.description.abstractCore outcome sets are critically important outcomes that should be measured in clinical trials. Their absence in atopic dermatitis is a form of research waste and impedes combining evidence to inform patient care. Here, we articulate the rationale for core outcome sets in atopic dermatitis and review the work of the international Harmonising Outcome Measures for Eczema group from its inception in Munich, 2010. We describe core domain determination (what should be measured), to instrument selection (how domains should be measured), culminating in the complete core outcome measurement set in Tokyo, 2019. Using a "road map," Harmonising Outcome Measures for Eczema includes diverse research methods including Delphi and nominal group techniques informed by systematic reviews of properties of candidate instruments. The 4 domains and recommended instruments for including in all clinical trials of atopic dermatitis are patient symptoms, measured by Patient-Oriented Eczema Measure and peak Numerical Rating Scale 11 for itch intensity over 24 hours, clinical signs measured using the Eczema Area and Severity Index, quality of life measured by the Dermatology Life Quality Index series for adults, children, and infants, and long-term control measured by either Recap of atopic eczema or Atopic Dermatitis Control Tool.en_US
dc.language.isoenen_US
dc.relation.ispartofJournal of Allergy and Clinical Immunologyen_US
dc.rights© 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).en_US
dc.subjectScience::Medicineen_US
dc.titleThe HOME Core outcome set for clinical trials of atopic dermatitisen_US
dc.typeJournal Articleen
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)en_US
dc.identifier.doi10.1016/j.jaci.2022.03.017-
dc.description.versionPublished versionen_US
dc.identifier.pmid35351441-
dc.identifier.scopus2-s2.0-85129445332-
dc.identifier.issue6en_US
dc.identifier.volume149en_US
dc.identifier.spage1899en_US
dc.identifier.epage1911en_US
dc.subject.keywordsAtopic Dermatitisen_US
dc.subject.keywordsEczemaen_US
dc.description.acknowledgementDetails of funding for each of the consensus meetings is outlined in the published meeting reports. The following additional funding sources contributed to facilitating the HOME COS development: National Institute for Health and Care Research Senior Investigator award to Prof Hywel Williams (RE 2374) funded travel costs to enable UK patients to participate in HOME meetings; National Institute for Health and Care Research Programme Grant for Applied Research RP-PG-0407-10177 ‘‘Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)’’ was used to support completion of the some of the systematic reviews, the cost of meetings and patient and public involvement (Prof Kim Thomas); NIH NIAMS A Community-based Assessment of Skin Care, Allergies, and Eczema: The CASCADE Trial grant number 5 R01 AR071057-05 and Oregon Clinical and Translational Research Institute (OCTRI) assisted with outcome evaluations and associated travel costs (Prof Eric Simpson); Laura Howells received a PhD studentship from the British Skin Foundation (Ref: 8016) for studies that informed this work.en_US
item.grantfulltextopen-
item.fulltextWith Fulltext-
Appears in Collections:LKCMedicine Journal Articles
Files in This Item:
File Description SizeFormat 
PIIS009167492200389X (1).pdf1.18 MBAdobe PDFThumbnail
View/Open

SCOPUSTM   
Citations 10

39
Updated on Feb 20, 2024

Web of ScienceTM
Citations 20

21
Updated on Oct 26, 2023

Page view(s)

56
Updated on Feb 27, 2024

Download(s) 50

60
Updated on Feb 27, 2024

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.